The estimated Net Worth of Gregory T Lucier is at least $26.6 Million dollars as of 8 August 2024. Mr. Lucier owns over 8,212 units of Nuvasive Inc stock worth over $2,649,735 and over the last 16 years he sold NUVA stock worth over $23,169,771. In addition, he makes $830,057 as Chairman of the Board at Nuvasive Inc.
Gregory has made over 52 trades of the Nuvasive Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 8,212 units of NUVA stock worth $199,962 on 8 August 2024.
The largest trade he's ever made was exercising 569,522 units of Nuvasive Inc stock on 26 February 2010 worth over $28,920,327. On average, Gregory trades about 20,255 units every 46 days since 2008. As of 8 August 2024 he still owns at least 66,660 units of Nuvasive Inc stock.
You can see the complete history of Mr. Lucier stock trades at the bottom of the page.
Gregory T. Lucier serves as Chairman of the Board of the Company. Mr. Lucier is currently Chief Executive Officer of Corza Health, Inc. Mr. Lucier previously served as Chief Executive Officer of NuVasive from May 2015 to November 2018. Mr. Lucier has served as a member of our Board of Directors since December 2013 and our Chairman of the Board since November 2018. Mr. Lucier has over 25 years of executive management experience and served as Chairman and Chief Executive Officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until its acquisition by Thermo Fisher Scientific Inc. in February 2014. Prior to joining Life Technologies, Mr. Lucier served as Chief Executive Officer and President at GE Medical Systems Information Technologies, Vice President for Global Services at GE Medical Systems and served as a corporate officer of the General Electric Corporation. Mr. Lucier’s executive experience in the biotechnology industry provides strategic and practical knowledge to our Board related to strategy, finance, regulatory, clinical research and other operational areas in our industry.
As the Chairman of the Board of Nuvasive Inc, the total compensation of Gregory Lucier at Nuvasive Inc is $830,057. There are 4 executives at Nuvasive Inc getting paid more, with J. Christopher Barry having the highest compensation of $5,425,440.
Gregory Lucier is 56, he's been the Chairman of the Board of Nuvasive Inc since 2018. There are 5 older and 14 younger executives at Nuvasive Inc. The oldest executive at Nuvasive Inc is Donald Rosenberg, 69, who is the Independent Director.
Gregory's mailing address filed with the SEC is C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE, NC, 28277.
Over the last 22 years, insiders at Nuvasive Inc have traded over $60,917,905 worth of Nuvasive Inc stock and bought 185,079 units worth $8,372,956 . The most active insiders traders include Jesse I Treu, James C Blair und Brian H Dovey. On average, Nuvasive Inc executives and independent directors trade stock every 11 days with the average trade being worth of $415,308. The most recent stock trade was executed by Marc W. Rosenbaum on 1 March 2023, trading 1,829 units of NUVA stock currently worth $72,703.
nuvasive® is a place where we create new and innovative products at a speed that drives our ability to deliver absolute responsiveness®, and gives us a competitive edge. at nuvasive, we empower our shareowners to influence results and significantly contribute to the success of the company. together we make nuvasive a leader in the spine industry with our unique focus on speed of innovation®. every member of the nuvasive family has the opportunity to improve the lives of patients through their work. these life-changing career paths show how hard work, a competitive spirit and your unwavering dedication to the patient can take you and your career to new places. in addition to being a great place to have a career, we’re also committed to giving back and supporting our communities. through an attitude of gratitude, nuvasive provides life-changing spinal surgery to disadvantaged communities through our nonprofit, the nuvasive spine foundation®, and offers patient-to-patient support through
Nuvasive Inc executives and other stock owners filed with the SEC include: